Available from: (cited 2025 Jun 11)
Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
Other advantages include: delivery forces that suit all demographics
If you have minimal abdominal fat, the thigh may be easier to use correctly than the abdomen
Specifically, consistent effect estimates were observed across multiple independent cohorts, as demonstrated for schizophrenia (FinnGen: OR = 0.65, 95% CI [0.560.76]
While the safety of GLP-1 RAs is well established, current scientific evidence on the efficacy of microdosing GLP-1 RAs is lacking and further research is required to assess its benefits at lower doses
